Reported 16 days ago
In November, AbbVie stands out as a strong pick within the elite group of Dividend Kings, boasting a remarkable 310% increase in its dividend payouts since its spinoff from Abbott Laboratories. Despite facing competition for its top-selling drug Humira, AbbVie has reported overall revenue growth and continues to invest in research and development, positioning itself for continued success. With a forward dividend yield of 3.26% and attractive valuation metrics, AbbVie is favored for its strong dividend history and growth prospects.
Source: YAHOO